Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis
Eighty-eight percent of patients continued adjuvant abemaciclib beyond 3 months, demonstrating high early persistence and tolerance of abemaciclib in patients with node-positive EBC in a real-world clinical practice cohort. Persistence was 93.3% among patients who had a dose reduction, suggesting that timely dose adjustments, when needed, can promote early persistence on abemaciclib, particularly when patient-felt AEs are most frequent and can be effectively managed.
Authors
- Madeline Richey (ORCID: https://orcid.org/0000-0002-5161-5182)
- Astra M. Liepa
- ERIKA BRECHTELSBAUER
- Brenda R. Grimes (ORCID: https://orcid.org/0000-0002-7883-7957)
- Kíria Karolline Gomes Moreira (ORCID: https://orcid.org/0000-0003-1490-6295)
- Lindsay A. Williams (ORCID: https://orcid.org/0000-0003-3842-4629)
- Raisa Volodarsky
- Kathryn Elizabeth Hudson (ORCID: https://orcid.org/0000-0002-4974-4428)
- Zhanglin Lin Cui (ORCID: https://orcid.org/0000-0002-7034-0946)
- Hatem Soliman (ORCID: https://orcid.org/0000-0002-1893-3808)
- Jingru Wang (ORCID: https://orcid.org/0009-0006-8683-1121)
- Wambui Gathirua-Mwangi
Institutions
- Eli Lilly (United States) (US)
- Texas Oncology (US)
- Moffitt Cancer Center (US)
- Flatiron Health (United States) (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1007/s40487-025-00385-9
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00